Eli Lilly and Healthcare Pharmaceuticals Launch Once-a-week Drug TrulicityTM
Eli Lilly and Healthcare Pharmaceuticals Launch Once-a-week Drug TrulicityTM for Type 2 Diabetes in Bangladesh
Eli Lilly and Healthcare Pharmaceuticals Launch Once-a-week Drug TrulicityTM for Type 2 Diabetes in Bangl adesh
- TrulicityTM is a once weekly injectable for Type 2 diabetes treatment
- Belongs to a different class of drugs called GLP-1 receptor agonists, it is not an insulin
- Comes in a single-dose pen, does not require mixing or measuring, and is convenient to administer
Dhaka, August 07, 2020 – Healthcare Pharmaceuticals Ltd. (HPL) and Eli Lilly and Company today announced the launch of Trulicity™ (dulaglutide) in Bangladesh. Trulicity™ is the first once-weekly, injectable medication designed to improve blood sugar control in adults with Type 2 diabetes.
Trulicity™ offers patient benefits beyond glycemic control and the convenience associated with a once-weekly dose. Studies done on Trulicity™ have established its cardiovascular safety and weight reduction potential.
Trulicity™ comes in an easy to use, single-dose pen that does not require mixing or measuring and can be administered at any time of the day, independent of meals. It is available in 0.75 mg and 1.5 mg doses. Special care has been taken in concealing the injector needle to address the fear of needles that some patients have.
Trulicity™ is part of a class of drugs known as a glucagon – like peptide (GLP-1) receptor agonists. It is not insulin and mimics the effects of GLP-1, a natural hormone that helps keep blood sugar levels normal, by helping the body release its own insulin after food intake.
“Trulicity™ will be marketed and distributed in Bangladesh by Healthcare Pharmaceuticals Ltd., a leading life science organization that believes in innovation, patient benefit and compliance. The launch of Trulicity™ will open newer avenues in diabetes management and provide health care professionals with an additional tool to manage diabetes,” said Mr Halimuzzaman, DMD & CEO, Healthcare Pharmaceuticals Ltd.
“Diabetes is a big burden on the healthcare system in Bangladesh. More than 8 million people live with diabetes in the country and their treatment needs vary,” said Luca Visini, Managing Director for India, Bangladesh, Sri Lanka and Nepal, Eli Lilly and Company. “Lilly has been a global leader in diabetes care since 1923. Trulicity™ is an important addition to our diabetes portfolio in Bangladesh and this launch is an important milestone in our journey to help more and more patients and their caregivers with the treatment support they need,” he added.
“Type 2 diabetes is a progressive disease and in Bangladesh many patients do not meet their treatment goals. Trulicity™ is a new, non-insulin, injectable that has been designed keeping patients’ needs and convenience in mind,” said Prof. A K Azad Khan, President, BADAS.
Trulicity™ is a prescription drug that should be taken only on advice from a registered MD (Internal Medicine) and Endocrinologist. When prescribed, it should be used as an adjunct to diet and exercise.
About Eli Lilly and Company:
Lilly is a global health care leader that unites caring with discovery to create medicines that make life better for people around the world. We were founded more than a century ago by a man committed to creating high-quality medicines that meet real needs, and today we remain true to that mission in all our work. Across the globe, Lilly employees work to discover and bring life-changing medicines to those who need them, improve the understanding and management of disease, and give back to communities through philanthropy and volunteerism. To learn more about Lilly, please visit us at lilly.com and lilly.com/newsroom.
About Lilly Diabetes:
Lilly has been a global leader in diabetes care since 1923, when we introduced the world’s first commercial insulin. Today we are building upon this heritage by working to meet the diverse needs of people with diabetes and those who care for them. Through research and collaboration, a broad and growing product portfolio, and a continued determination to provide real solutions—from medicines to support programs and more—we strive to make life better for all those affected by diabetes around the world. For more information, visit www.lillydiabetes.com
About Healthcare Pharmaceuticals Ltd.
Healthcare Pharmaceuticals Ltd. is one of the largest companies in the pharmaceutical industry in Bangladesh and leading life science organization. We always believe in innovation and patient benefit and compliance. Our prime focus always remains on quality. It leads us to tie up with reputed multinational pharma Eli Lilly for making available their novel medicine for the patients of Bangladesh. We have a strong & international standard distribution network & cold chain infrastructure. Our strength is our quality practice in every steps of our operations (whether it is manufacturing, QA, marketing, communication with HCP or distribution of products).
We got accreditation from reputed international bodies like TGA (Therapeutic Goods Administration), Australia, NPRA (National Pharmaceutical Regulatory Agency) of Malaysia and we are on the process of accreditation by US FDA. Currently, we have footprints in more than 20 countries exporting our quality medicine.
For any additional information, please contact:
HPL:
Dr Shek Sady Khan
Eli Lilly and Company:
Vishwanath Prasad
prasad_vishwanath_in@lilly.com
